CRL · NYSE · Healthcare · Diagnostics and Research
$338.04-0.9%Nov 13 close
Figures through September 26, 2026, from the 10-Q filed November 4, 2026
Just reported
From Charles River Laboratories International, Inc.'s results release of November 4, 2026; its quarterly report has since been filed.
Actual
$982.7M
-2.2% y/y
-2.1% q/q
Guided
—
No guide given
Actual
$6.86
Guided
—
No guide given
EPS, adjusted: $3.09
Actual
| Measure | 3 months toSep 26, 2026 | 3 months toSep 27, 2025 | Change |
|---|---|---|---|
| Total Revenue | $982.7M | $1B | -2.20% |
| Profit | $333.1M | $54.4M | +512.01% |
| Profit per share | $6.86 | $1.10 | +523.64% |
| Free Cash Flow | $207.3M | $178.2M | +16.29% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Charles River Laboratories International, Inc. reported on November 4, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com. # # # Investor
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Charles River Laboratories International, Inc.’s Item 2.02 8-K filed November 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
$202.6M
+51% y/y
+69% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.